FSD Pharma

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc has announced the appointments of David Allan and John McGraw to its advisory board. Allan is principal at Cresswell Advisors Inc and has worked in several leading biotechnology companies that were acquired by names like Bristol Myers Squibb and Pfizer.

FSD Pharma adds two new faces to its advisory board

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the appointment of David Allan and John McGraw, PhD, MSc, to the Company's Advisory Board. “Mr. Allan and Dr. McGraw both have impressive careers in the field of healthcare and biotechnology underscored by tremendously successful exits and we are excited to welcome them to ou

FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today, pursuant to a court endorsement, the cancellation of 504,888 Class B subordinate voting shares previously issued to the Company's former Chief Executive Officer, Dr. Raza Bokhari. This follows the prior cancellation of 156,278 Class B subordinate voting shares previous

FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc. announced that it is expanding its management and advisory teams.

FSD Pharma announces expansion of its management and advisory teams

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the following corporate updates; 1. FSD Pharma adds industry leaders Jason Sawyer and Dr. Ravinder Kumar to its Advisory Board. Jason Sawyer brings 29 years of alternative investment and business experience to FSD's drug development efforts. He currently serves as the G

FSD Pharma Issues Corporate Updates

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the filing of its Annual Report on Form 20-F for the year ended December 31, 2021, audited financial results for the fourth quarter and full year then ended and accompanying management discussion and analysis. These filings are available for review under the Company's SE

FSD Pharma Announces Filing of Year-End 2021 Results

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Crystal Research Associates LLC has released an Executive Informational Overview® (EIO) on FSD Pharma. The 58 page paid report can be found on FSD Pharma's website. For the past two decades, Crystal Research Associates, LLC has successfully articulated the exceptio

FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC

Arena Pharmaceuticals

Clever Leaves Holdings Inc

Flora Growth Corp

HEXO Corp

High Tide

Innovative Industrial Properties

Tilray Brands

22nd Century Group

cbdMD Inc

WM Technology

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.

11 Marijuana Stocks on Fire to Close February

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it has entered into a firm agreement in connection with the sale of its former cannabis processing facility (the “Facility”) located in Cobourg, Ontario and the 64.43 acre property on which the facility is located (the “Transaction”). In consideration for the purch

FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the launch of its newly designed website. The new site conveys the Company's emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. To vi

FSD Pharma Announces Launch of New Corporate Website

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, warmly congratulates Eleanor N. Fish, Ph.D., a member of its Research and Clinical Advisory Board, on her appointment to the Order of Canada. Dr. Fish was named a Member of the Order for her contributions to immunology, including her groundbreaking studies on the use of interferon-alph

FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright Bioconnect Conference to be held virtually on January 10-13, 2022. Mr. Durkacz's presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET on January 10

FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc said its board of directors has authorized the repurchase by the company of up to 2 million of its subordinate Class B voting shares, being approximately 5% of its issued and outstanding subordinate voting shares, from time to time over the next 12 months. The company said the share repurchase programme will allow it to use its excess cash reserves to strategically return value to shareholders.

FSD Pharma says board authorizes repurchase by the company of up to 2 million of its subordinate Class B voting shares

FSD Pharma says its board has authorized the repurchase by the company of up to 2 million of its subordinate Class B voting share

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc announced that it has formed a regulatory advisory board and has appointed Joga Gobburu and Mary Melnyk as members. The Toronto-based company said that the regulatory board was formed by Lakshmi P.

FSD Pharma says it formed new regulatory advisory board, appoints Joga Gobburu and Mary Melnyk as members

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it has formed a Regulatory Advisory Board (“RAB”) and has appointed Joga Gobburu, B.Pharm. (Hons), M.Sc. (Hons), Ph.D., M.B.A., and Mary Melnyk, M.Sc., Ph.D., as members. A world-recognized scientific leader in pharmacometrics, Dr. Gobburu is a Professor at the Sch

FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D.

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright 2nd Annual Virtual Psychedelics Conference to be held on December 6, 2021. Mr. Durkacz's presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET and ac

FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc shared pre-clinical data, demonstrating the potentially disease-modifying effects of Lucid-MS —the company's lead drug candidate for the potential treatment of multiple sclerosis (MS) in the animal models of MS.  The Toronto-based biotech company said that based on more than a decade of research, Lucid-MS is a patented neuroprotective new chemical entity that affects protein citrullination and myelin structure, which are associated with the severity of MS lesions.

FSD Pharma shares pre-clinical data revealing positive effects of Lucid-MS in treating multiple sclerosis in mouse models

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it is sharing pre-clinical data, supported by an explanatory video, demonstrating the potentially disease-modifying effects of Lucid-MS, the Company's lead drug candidate for the potential treatment of multiple sclerosis (“MS”), in the animal models of MS. Based on

FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc said it has expanded its team by appointing Dr Eleanor N. Fish to its Research and Clinical Advisory Board.

FSD Pharma announces appointment of Dr Eleanor N. Fish to its Research and Clinical Advisory Board

Focused on lead anti-inflammatory drug FSD-201 Launched Phase 2 study of drug known as micro PEA in December 2020 Developing drugs to treat gastrointestinal diseases in dogs and cats What FSD Pharma does: FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) is a publicly-traded holding company that owns subsidiary FSD Pharma BioSciences Inc, a specialty biotech pharmaceutical R&D firm focused on developing multiple applications of its lead anti-inflammatory drug FSD-201. The drug is now one of several therapeutics being advanced that could help reduce severe and deadly lung infection in coronavirus (COVID-19) patients.

FSD Pharma moving into psychedelic and sees legacy anti-inflammatory drug as potential coronavirus therapy

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc said it has expanded its team by appointing Eleanor N. Fish to its Research and Clinical Advisory Board.

FSD Pharma announces appointment of Eleanor N. Fish to its Research and Clinical Advisory Board

TORONTO--(BUSINESS WIRE)---- $HUGE #RestoreFSD--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the appointment of Eleanor N. Fish, Ph.D., to its Research and Clinical Advisory Board. Dr. Fish, an accomplished researcher in the areas of immunology and inflammatory disorders, and member of the Government of Canada's Expert Scientific Panel to the Chief Scientific Ad

FSD Pharma Expands Research and Clinical Advisory Board with Appointment of World-Renowned Immunologist and Cytokine Expert Dr. Eleanor N. Fish

FSD Pharma Inc said it has entered into an agreement with Covar Pharmaceuticals Inc, a contract development and manufacturing services organization, to start work on providing research quantities of its drug candidate, Lucid-PSYCH, on an exclusive basis for further clinical evaluation.  FSD has selected Lucid-PSYCH (formerly Lucid-201), a psychoactive compound, to advance its research into the treatment of major depressive disorders based on analysis of the drug candidate's pharmaceutical and metabolic properties processed via machine learning algorithms, as well as for its potential proprietary position.

FSD Pharma strikes deal with Covar Pharmaceuticals to support the development of drug candidate Lucid-PSYCH

TORONTO--(BUSINESS WIRE)---- $HUGE #RestoreFSD--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today it has entered into an agreement with Covar Pharmaceuticals Inc. (“Covar”), a contract development and manufacturing services organization (“CDMO”), to commence work on providing research quantities of FSD's drug candidate, Lucid-PSYCH, on an exclusive basis for further

News for FSD Pharma Stock (HUGE)